PCAT-1 facilitates breast cancer progression via binding to RACK1 and enhancing oxygen-independent stability of HIF-1α

Jianlong Wang,1,5 Xuyi Chen,2,5 Haijuan Hu,1,5 Mengting Yao,4 Yanbiao Song,1 Aimin Yang,1 Xiuhua Xu,1 Ning Zhang,3 Jianzhao Gao,4 and Bin Liu1

Hypoxia induces a series of cellular adaptive responses that enable promotion of inflammation and cancer development. Hypoxia-inducible factor-1α (HIF-1α) is involved in the hypoxia response and cancer promotion, and it accumulates in hypoxia and is degraded under normoxic conditions. Here we identify prostate cancer associated transcript-1 (PCAT-1) as a hypoxia-inducible long non-coding RNA (lncRNA) that regulates HIF-1α stability, crucial for cancer progression. Extensive analyses of clinical data indicate that PCAT-1 is elevated in breast cancer patients and is associated with pathological grade, tumor size, and poor clinical outcomes. Through gain- and loss-of-function experiments, we find that PCAT-1 promotes hypoxia-associated breast cancer progression including growth, migration, invasion, colony formation, and metabolic regulation. Mechanistically, PCAT-1 directly interacts with the receptor of activated protein C kinase-1 (RACK1) protein and prevents RACK1 from binding to HIF-1α, thus protecting HIF-1α from RACK1-induced oxygen-independent degradation. These findings provide new insight into lncRNA-mediated mechanisms for HIF-1α stability and suggest a novel role of PCAT-1 as a potential therapeutic target for breast cancer.

INTRODUCTION
Breast cancer is a major public health problem, and it is the most commonly diagnosed cancer among women. The implementation of breast cancer early diagnosis, together with local surgery and radiotherapy and systemic pharmacological treatments, has resulted in substantial improvement in the therapeutic effects on breast cancer.12 However, cancer progression and the spread of cancer cells to other organs are the cause of death in the vast majority of patients, and the processes are complicated and involve many complex epigenetic changes.3,4 Since the pathogenic mechanisms of cancer progression are not fully understood, more studies are needed to discover and develop effective molecules and targets for diagnosis and treatment.

Hypoxia in the tumor microenvironment is associated with inflammation, tumorigenesis, and therapeutic resistance.5,7 Although hypoxia occurs at different stages of breast cancer development, it is unclear how hypoxia affects the cells during transformation. Hypoxia-inducible factor-1 (HIF-1) is a key regulator of the hypoxia response and cancer promotion.5,7 It is essential for the cellular response to hypoxia, including angiogenesis, energy metabolism, cell survival, invasion and metastasis.5,7 HIF-1 is a heterodimer composed of HIF-1α and HIF-1β subunits. HIF-1β is maintained constitutively, whereas HIF-1α accumulates rapidly in hypoxia and is degraded under normoxic conditions. In normoxia, HIF-1α is degraded by oxygen-dependent prolyl hydroxylation, ubiquitination, and proteasomal degradation.11 Under hypoxic conditions, HIF-1α evades the oxygen-dependent degradation, allowing it to translocate into the cell nucleus to form the transcriptional HIF-1α complex.10 Several studies have shown that there are oxygen-independent mechanisms of HIF-1α degradation under hypoxic conditions, including heat shock protein 90 (HSP90) and receptor of activated protein C kinase-1 (RACK1).12–14 HSP90 binds to the HIF-1α PAS domain to prevent its degradation. RACK1 competes with HSP90 for binding to HIF-1α, links HIF-1α to Elongin-C, and promotes HIF-1α degradation in an oxygen-independent manner.12,15 Thus, equilibrium between HIF-1α/RACK1 and HIF-1α/HSP90 may play a key role in maintaining HIF-1α stability, as well as cancer progression.

Long non-coding RNAs (lncRNAs) have emerged as important molecules in carcinogenesis, with various biological effects, such as genome modification, transcriptional activation, and transcriptional interference.16–18 They have been implicated as prospective biomarkers for early cancer diagnosis, with the potential to serve as new targets for cancer treatment.19,20 Previous studies have identified

Received 16 September 2020; accepted 25 February 2021; https://doi.org/10.1016/j.omtn.2021.02.034.

*These authors contributed equally

Correspondence: Bin Liu, Central Laboratory, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, China.
E-mail: liubin810103@yahoo.com
Correspondence: Jianzhao Gao, School of Mathematical Sciences and LPMC, Nankai University, Tianjin 300071, China.
E-mail: gaojz@nankai.edu.cn
that lots of hypoxic-reactive lncRNAs are functionally characterized and have crucial effects on cancer progression.\textsuperscript{21} Prostate cancer associated transcript-1 (PCAT-1) is identified as a prostate cancer-overexpressed lncRNA, and it contributes to prostate cancer progression through regulation of target genes.\textsuperscript{22} The high expression of PCAT-1 has been observed in several types of cancers, including colorectal cancer,\textsuperscript{23} esophageal squamous cell carcinoma,\textsuperscript{24} hilar cholangiocarcinoma,\textsuperscript{25} osteosarcoma,\textsuperscript{26} and hepatocellular carcinoma.\textsuperscript{27} It has been shown to be involved in impairment of double-stranded DNA break repair, cancer cell proliferation, epithelial-mesenchymal transition, migration, and invasion.\textsuperscript{28–31} A recent report shows that PCAT-1 overexpression is also observed in breast cancer tissues.\textsuperscript{32} However, there is no previous report of PCAT-1 regulating hypoxia-related cancers. Currently, the clinical significance of PCAT-1 in the context of breast cancer and the molecular mechanisms by which it regulates remain largely unclear.

In this study, through the investigation of lncRNA in breast cancer, we identify that PCAT-1 is one of the significantly upregulated lncRNAs under hypoxic conditions. We reveal that PCAT-1 is critical for maintaining the stability of HIF-1α in hypoxic breast cancer cells, which is related to advanced disease progression and poor prognosis. We elucidate that PCAT-1 interacts with RACK1, which mediates oxygen-independent HIF-1α stability, thereby establishing PCAT-1 as an important lncRNA in breast cancer.

RESULTS

The expression of PCAT-1 is induced after hypoxia treatment

In order to determine the involvement of lncRNAs in hypoxia-related cancer progression, we selected 30 cancer-associated lncRNAs (listed in Table S1) according to previous studies and analyzed their expression in MDA-MB-231 breast cancer cells in hypoxia and normoxia.\textsuperscript{30,31} Compared with normoxic conditions, 10 lncRNAs with >2-fold expression changes were identified in hypoxia (Figure 1A). Moreover, we checked the expression of these lncRNAs and found 7 of them upregulated by >2-fold in MDA-MB-231 cells treated with cobalt chloride (CoCl$_2$) (Figure 1B), which was used to create a pseudohypoxic environment. These lncRNAs include 4 of those induced in physical hypoxia (Figure 1C). PCAT-1 was one of the most abundantly expressed lncRNAs in response to CoCl$_2$ treatment and displayed a time- and concentration-dependent induction (Figures 1D and 1E; Figures S1A–S1C). Similarly, a time-dependent increase of PCAT-1 was observed in MDA-MB-231 cells under hypoxic conditions (Figure 1F), confirming that PCAT-1 is a hypoxia-responsive lncRNA and is probably related to the HIF-1α signaling pathway.

PCAT-1 expression is associated with poor breast cancer prognosis

To assess the pathological and clinical value of PCAT-1 in breast cancer, we measured PCAT-1 expression in a panel of 71 matched pairs of clinical specimens containing breast cancer tissues and the normal adjacent tissues. This showed that PCAT-1 was significantly upregulated in the cancer tissues compared with the normal adjacent tissues ($p < 0.001$; Figure 1G). Moreover, statistical analysis showed that PCAT-1 overexpression was strongly correlated with advanced tumor stage ($p < 0.001$; Figure 1H) and tumor size ($p < 0.001$; Figure 1I).

To further validate the data from our studies, we surveyed public data of The Cancer Genome Atlas (TCGA) breast cancer study using the cBioPortal platform and explored the correlation between PCAT-1 gene alteration and the clinicopathological characteristics of 735 breast cancer patients (Table S2). The analyses revealed that PCAT-1 amplification was correlated with advanced tumor stage ($p = 0.008$) and tumor size ($p = 0.002$; Table 1), whereas no significant relationship with any other clinical characteristics was observed. Moreover, PCAT-1 expression was higher in Luminal B than in other subtypes of breast tumors (Figure S1D). We evaluated PCAT-1 gene alteration in relation to overall survival (OS) and disease-free survival (DFS) data on the patients (Table S2). Kaplan-Meier survival analysis was performed to compare the outcomes of patients dichotomized by PCAT log$_2$ copy number value. Patients with PCAT-1-amplification copy number had a significantly worse OS ($p < 0.001$) (Figure 1J) and DFS ($p = 0.004$) (Figure 1K), and similar results were also observed in patients with different tumor stages (Figures S1E and S1F). In addition, similar to the prognostic values of tumor stage (I + II versus III + IV), tumor size ($\leq 2$ cm versus $> 2$ cm), and lymph node metastasis (N0 versus N1–3), the univariate Cox proportional hazards showed that PCAT-1 amplification was another strong prognostic predictor for poor OS (hazard ratio [HR] = 2.645, $p < 0.001$) and DFS (HR = 2.049, $p = 0.005$; Table 2). Furthermore, multivariate analysis was conducted to determine risk assessment related to OS and DFS. PCAT-1 amplification was identified as an independent prognostic factor for OS (HR = 1.948, $p = 0.015$, multivariate analysis) and DFS (HR = 1.829, $p = 0.025$, multivariate analysis; Table 2). These results indicated that PCAT-1 could be used as an independent indicator of prognosis in breast cancer patients.

PCAT-1 promotes breast cancer progression

To ascertain the potential role of PCAT-1 in breast cancer, we detected the expression of PCAT-1 in breast cancer cells MCF-7, MDA-MB-231, MDA-MB-468, and T47D and normal breast epithelial cell MCF10A. Compared with MCF-7, MDA-MB-468, and T47D cells with poor invasive capacity, the highly invasive MDA-MB-231 cells had higher PCAT-1 expression (Figure 2A), while MCF-7, MDA-MB-468, T47D, and MCF10A cells had a low level of PCAT-1, suggesting that PCAT-1 might be related to cell invasion in breast cancer. Similar to MDA-MB-231 cells, PCAT-1 expression was also induced in MCF-7 cells by CoCl$_2$ under pseudohypoxia or under hypoxic conditions (Figure 2B).

The cell’s response to pathological hypoxia is associated with many critical aspects of cancer. To further investigate the biological significance of PCAT-1 in breast cancer, we knocked down the expression of PCAT-1 with two independent small interfering RNAs (siRNAs). Moreover, lentiviral PCAT-1 small hairpin RNA (shRNA) (shRNA-PCAT-1) and empty vector (shRNA-Control) were also stably transfected in MDA-MB-231 cells, and the related phenotypes in the cells were examined. The functional assays revealed that PCAT-1 knockdown significantly impaired cell growth, migration, invasion, and
colony formation in hypoxia (Figures 2C–2F), whereas PCAT-1 over-expression had the opposite effects (Figure S2). In addition, with normalization to cell number, we found that the hypoxia-induced extracellular acidification rate (ECAR) (Figure 2G) and lactate production (Figure 2H) were significantly reduced in the PCAT-1-knockdown MDA-MB-231 cells under hypoxic conditions, indicating that PCAT-1 is essential for glycolytic metabolism in the cells.

**PCAT-1 contributes to HIF-1α stability**

HIF-1α is a core regulator of cellular adaptation to hypoxia, which could regulate lncRNAs at the transcriptional level via hypoxia response elements (HREs). In the present study, no HREs were found in the PCAT-1 promoter *in silico* prediction. Consistent with this, inhibition of either HIF-1α or HIF-2α did not significantly affect PCAT-1 induction in hypoxia (Figure S3), suggesting that
PCAT-1 is not a direct HIF target lncRNA. To determine the roles of PCAT-1 in the HIF-1α signaling pathway, PCAT-1 was overexpressed in MCF-7 cells. We found that HIF-1α protein expression was increased in normoxia as well as in hypoxia (Figure 3A). However, HIF-1α mRNA expression was not changed. In addition, we investigated whether PCAT-1 regulates HIF-1α mRNA stability. We treated the cells with actinomycin D, which blocks de novo mRNA synthesis, and the HIF-1α mRNA stabilization was not affected by PCAT-1 overexpression (Figure 3B), suggesting that HIF-1α mRNA transcription and degradation are not regulated by PCAT-1. Additionally, the cells were exposed to hypoxia and then recovered in normoxia, and we found that the half-lives of HIF-1α protein were increased from 2.5 ± 0.3 to 6.5 ± 0.7 min as a consequence of PCAT-1 overexpression, indicating that PCAT-1 overexpression yielded a significant delay of HIF-1α protein degradation (Figure 3C). These results revealed that PCAT-1 overexpression increased HIF-1α expression by enhancing the stability of HIF-1α protein. In addition, PCAT-1 was depleted in MDA-MB-231 cells. HIF-1α protein expression was obviously decreased in the cells after knockdown of PCAT-1 in a hypoxic environment (Figure 3D), while HIF-1α mRNA expression and stabilization were not changed (Figure 3E). We also found that HIF-1α protein degraded more quickly during reoxygenation in the PCAT-1-knockdown cells (Figure 3F), and the half-lives of HIF-1α protein were decreased from 7.2 ± 1.1 to 3.8 ± 0.6 min, suggesting that depletion of PCAT-1 decreased the HIF-1α protein stability.

Table 1. The relationship between PCAT-1 gene alteration and clinicopathological characteristics in breast cancer patients

| Clinicopathologic characteristics | PCAT-1 gene alteration | Number of cases | p value |
|-----------------------------------|------------------------|-----------------|---------|
|                                   | Amplification (%)      | Low (%)         |         |
| Age (years)                       |                        |                 |         |
| ≤60                               | 122 (29)               | 365 (71)        | 427     | 0.742 |
| >60                               | 92 (30)                | 216 (70)        | 308     |       |
| Tumor stage                       |                        |                 |         |
| I + II                            | 61 (38)                | 100 (62)        | 161     | 0.008** |
| III + IV                          | 153 (27)               | 421 (73)        | 574     |       |
| Tumor size                        |                        |                 |         |
| ≤2 cm                             | 41 (21)                | 157 (79)        | 198     | 0.002** |
| >2 cm                             | 173 (32)               | 364 (68)        | 537     |       |
| Lymph node metastasis             |                        |                 |         |
| N0                                | 97 (26)                | 277 (74)        | 374     | 0.062 |
| N1–3                              | 117 (32)               | 244 (68)        | 361     |       |
| Race                              |                        |                 |         |
| Other                             | 50 (34)                | 95 (66)         | 145     | 0.098 |
| White                             | 144 (27)               | 385 (73)        | 529     |       |
| Radiation                         |                        |                 |         |
| No                                | 93 (29)                | 225 (71)        | 318     | 0.934 |
| Yes                               | 111 (29)               | 273 (71)        | 384     |       |

Fisher’s exact test was used to determine the correlation between PCAT-1 gene alteration and the clinicopathological characteristics. The cutoff point is set as the value yielding maximum sum of sensitivity and specificity for disease-free survival analysis. **p < 0.01.

Furthermore, to determine whether PCAT-1 modulated HIF-1α activity, we investigated the expression of HIF-1α target genes such as FLTL1, VEGFA, ANGPT1A, CCNG2, SOX9, PDK1, PLOD2, LDHA, JMJD1A, GLUT1, and BNIP3 in the cells. PCAT-1 knockdown attenuated the expression of these genes in MDA-MB-231 cells in hypoxia, without a significant change of the gene expression in normoxia (Figure 3G). Reciprocally, PCAT-1 overexpression in MCF-7 cells induced the expression of HIF-1α target genes in hypoxia (Figure 3H). In addition, we found that HIF-1α transfection significantly abrogated the effects of PCAT-1 depletion on hypoxia-induced cell phenotypes in PCAT-1-silenced MDA-MB-231 cells (Figure S4), indicating that HIF-1α was a functional target of PCAT-1 in breast cancer cells.

PCAT-1 protects HIF-1α from RACK1-mediated oxygen-independent degradation

To determine whether the effects of PCAT-1 on the stability of HIF-1α protein are related to prolyl hydroxylase, HA-HIF-1α (P402A/P564A), which contained the proline-to-alanine substitutions and resisted hydroxylation, was transfected in MDA-MB-231 cells. PCAT-1 knockdown attenuated the expression of these genes in MDA-MB-231 cells in hypoxia, without a significant change of the gene expression in normoxia (Figure 3G). Reciprocally, PCAT-1 overexpression in MCF-7 cells induced the expression of HIF-1α target genes in hypoxia (Figure 3H). In addition, we found that HIF-1α transfection significantly abrogated the effects of PCAT-1 depletion on hypoxia-induced cell phenotypes in PCAT-1-silenced MDA-MB-231 cells (Figure S4), indicating that HIF-1α was a functional target of PCAT-1 in breast cancer cells.
PCAT-1 siRNA and RACK1 siRNA, and we found that PCAT-1 siRNA increased HIF-1α protein levels by 2.3-fold and blocked the degradation of HIF-1α in PCAT-1-knockdown cells (Figure 4C). Moreover, we found that RACK1 knockdown notably improved HIF-1α protein stability in MCF-7 cells cotransfected with PCAT-1 and HA-HIF-1α (P402A/P564A) (Figure 4D). In addition, PCAT-1 was overexpressed in MCF-7 cells and then the cells were treated with the HSP90 inhibitor (P402A/P564A) (Figure 4D). The results showed that PCAT-1 could not interact with RACK1 (Figure 5B). Consistently, RNA immunoprecipitation (RIP) assays further confirmed that PCAT-1 directly interacted with RACK1 (Figure 5C). Moreover, a series of PCAT-1 truncated fragment analyses demonstrated that the 3rd terminal (nucleotides 801–1200) region of the PCAT-1 was required for direct interaction with RACK1, which was confirmed by RNA pull-down assays (Figure 5D). However, RNA pull-down and RIP assays were conducted, and the results showed that PCAT-1 could not interact with HSP90 (Figure 5E).

**Table 2. Univariate and multivariate Cox regression analyses of overall survival and disease-free survival in breast cancer patients**

| Covariate                              | Univariate analysis | Multivariate analysis |
|----------------------------------------|---------------------|-----------------------|
|                                        | HR                  | 95% CI                | p value | HR                  | 95% CI                | p value |
| **Overall survival**                   |                     |                       |         |                     |                       |         |
| Age (≤60 versus >60)                   | 1.826               | 1.122–2.971           | 0.015*  | 2.097               | 1.209–3.637           | 0.008** |
| Tumor stage (I + II versus III + IV)   | 2.777               | 1.697–4.545           | 0.000** | 3.587               | 1.713–7.512           | 0.001** |
| Tumor size (≤2 cm versus >2 cm)        | 2.327               | 1.217–4.448           | 0.011*  | 1.478               | 0.733–2.980           | 0.275   |
| Lymph node metastasis (N0 versus N1–3) | 2.132               | 1.284–3.537           | 0.003** | 1.280               | 0.615–2.661           | 0.509   |
| Race (Other/White)                     | 0.639               | 0.361–1.130           | 0.124   | 0.577               | 0.319–1.045           | 0.070   |
| Radiation (No/Yes)                     | 0.572               | 0.343–0.953           | 0.032*  | 0.366               | 0.203–0.660           | 0.001** |
| PCAT-1 gene alteration (low versus amplification) | 2.364               | 1.458–3.833           | 0.000** | 1.948               | 1.135–3.341           | 0.015*  |
| **Disease-free survival**              |                     |                       |         |                     |                       |         |
| Age (≤60 versus >60)                   | 0.817               | 0.478–1.396           | 0.459   | 0.912               | 0.516–1.615           | 0.753   |
| Tumor stage (I + II versus III + IV)   | 3.109               | 1.870–5.166           | 0.000** | 3.576               | 1.731–7.386           | 0.001** |
| Tumor size (≤2 cm versus >2 cm)        | 2.089               | 1.086–4.017           | 0.027*  | 1.331               | 0.669–2.644           | 0.415   |
| Lymph node metastasis (N0 versus N1–3) | 1.707               | 1.021–2.854           | 0.042*  | 0.965               | 0.464–2.096           | 0.924   |
| Race (Other/White)                     | 0.525               | 0.297–0.927           | 0.026*  | 0.553               | 0.311–0.981           | 0.043*  |
| Radiation (No/Yes)                     | 0.923               | 0.553–1.538           | 0.757   | 0.599               | 0.338–1.061           | 0.079   |
| PCAT-1 gene alteration (low versus amplification) | 2.049               | 1.238–3.392           | 0.005** | 1.829               | 1.078–3.103           | 0.025*  |

HR, hazard ratio; 95% CI, 95% confidence interval. *p < 0.05 and **p < 0.01.

PCAT-1 interacts with RACK1 that mediates HIF-1α stability

RACK1 could compete with HSP90 for binding to HIF-1α and be involved in HIF-1α degradation. Given the established interaction of RACK1 with HIF-1α, we sought to analyze the mechanistic role of PCAT-1 in HIF-1α stability by focusing on the interaction between PCAT-1 and RACK1. We first explored the possible interaction between PCAT-1 and RACK1 through bioinformatic analysis (catRAPID), which could predict the protein-RNA associations by estimating the interaction propensity between amino acids and nucleotides. Results from catRAPID fragments analysis showed that the 1093–1172 and 1288–1367 nucleotide positions of the PCAT-1 sequence may bind to the 217–268 amino acid residues of the RACK1 protein with high affinity (Figure 5A).

To validate the physical interaction between PCAT-1 and RACK1, we performed RNA pull-down followed by immunoblot using RACK1 antibody in MDA-MB-231 cells. The results indicated that PCAT-1 was able to interact with RACK1 (Figure 5B). Consistently, RNA immunoprecipitation (RIP) assays further confirmed that PCAT-1 directly interacted with RACK1 (Figure 5C). Moreover, a series of PCAT-1 truncated fragment analyses demonstrated that the 3rd terminal (nucleotides 801–1200) region of the PCAT-1 was required for direct interaction with RACK1, which was confirmed by RNA pull-down assays (Figure 5D). However, RNA pull-down and RIP assays were conducted, and the results showed that PCAT-1 could not interact with HSP90 (Figure 5E).

To further clarify the functional relevance of the PCAT-1/RACK1 interaction, full-length and truncated PCAT-1 (nucleotides 1–800 and 1201–1992) were overexpressed in MCF-7 cells. The results showed that, compared with the full-length PCAT-1, the ability of RACK1 binding-deficient mutant PCAT-1 to maintain HIF-1α stability and induce HIF-1α target genes was significantly impaired (Figures 5E and 5F). Moreover, overexpression of the truncated PCAT-1 (nucleotides 801–1200) in PCAT-1-silenced MDA-MB-231 cells restored the hypoxia-associated cancer phenotypes in the cells (Figures 5G–5I). Full-length RACK1 consists of seven tandemly repeated WD40 domains. To map which WD40 domain on Rack1 is required for PCAT-1 interaction, we generated several deletion mutants of RACK1 consisting of WD2–7, WD3–7, WD4–7, WD5–7, WD6–7, and WD7. The RIP assays revealed that constructs containing the sixth WD40 domain could bind to PCAT-1 (Figure 5K), suggesting that the sixth WD40 domain was responsible for the PCAT-1/RACK1 interaction.
Figure 2. PCAT-1 facilitates the progression of breast cancer

(A) Expression of PCAT-1 in MCF-7, MDA-MB-231, MDA-MB-468, T47D, and MCF10A cells was analyzed by quantitative real-time PCR and normalized to GAPDH expression. (B) Expression of PCAT-1 in MCF-7 cells treated with different concentrations of cobalt chloride for 24 h or under hypoxic conditions. MDA-MB-231 cells were

(legend continued on next page)
PCAT-1 reduces the binding between RACK1 and HIF-1α.

To evaluate the effect of PCAT-1 on RACK1 binding to HIF-1α, MDA-MB-231 cells transfected with shRNA-PCAT-1 were treated with MG132. Immunoprecipitation results showed that PCAT-1 knockdown reduced HIF-1α binding to HSP90 but significantly increased the binding efficiency between HIF-1α and RACK1 (Figure 6A). Moreover, MCF-7 cells were cotransfected with PCAT-1 and HA-HIF-1α (P402A/P564A) under hypoxic conditions, and this showed that PCAT-1 overexpression significantly suppressed HA-HIF-1α binding to RACK1 (Figure 6B). Moreover, HSP90 inhibition by 17-AAG increased the binding efficiency between RACK1 and HIF-1α, while it can be abolished by PCAT-1 overexpression. We further investigated the effect of PCAT-1 on RACK1 dimerization, which is necessary in HIF-1α activation. FLAG-RACK1 was transfected in HEK293 cells, and then it was separated by anti-FLAG antibody immobilized on agarose resin. We further used the resin to pull down endogenous RACK1 from the MDA-MB-231 cells transfected with shRNA-PCAT-1, and the results showed that PCAT-1 knockdown increased RACK1 dimerization under hypoxic conditions (Figure 6C). Consistent with the previous study showing that serine phosphorylation of RACK1 was required for its dimerization and HIF-1α degradation,33 we found that PCAT-1 knockdown also enhanced RACK1 phosphorylation (Figure 6D).

Suppression of breast cancer progression by targeting PCAT-1 in vivo

To evaluate the biological function of PCAT-1 in vivo, MDA-MB-231 cells stably transfected with shRNA-PCAT-1 or shRNA-Control lentiviral particles were inoculated into the right flank of nude mice (n = 8/group). Five weeks later, compared with shRNA-Control, the shRNA-PCAT-1 tumor growth was dramatically delayed (Figures 7A–7C).

We further injected the cells into the tail veins of nude mice in order to evaluate the metastatic potential of the cells. The mice were sacrificed 8 weeks later, and the lung and liver tissues were obtained for detection of human genomic DNA by quantitative real-time PCR according to the previous studies.34 We found that less human genomic DNA was present in the lungs and livers of mice injected with PCAT-1-silenced cells compared with the control group (Figures 7D and 7E), indicating that PCAT-1 knockdown suppressed circulating tumor cell colonization and prevented metastasis of breast cancer cells to the lung and liver. Moreover, we performed hematoxylin and eosin (H&E) and in situ hybridization staining (ISH) for PCAT-1 in the xenografts, livers, and lungs, and this showed that PCAT-1 expression was significantly downregulated in the shRNA-PCAT-1 group compared with the shRNA-Control group (Figure 7F–7H). Taken together, these results suggested that PCAT-1 knockdown significantly suppressed breast cancer progression and metastasis in vivo, which further confirmed the carcinogenic effects of PCAT-1 in breast cancer.

DISCUSSION

Hypoxia is common in solid tumors, and it modulates cancer progression as well as therapeutic response. Recently, more and more observations have recognized that lncRNA can act as a regulator of cellular responses in hypoxia. Under hypoxic conditions, lncRNA plays regulatory roles through a variety of potential mechanisms such as epigenetics, lncRNA-microRNA (miRNA) interaction, and lncRNA-protein interaction.35–37 However, only a few have been confirmed in terms of the detailed mechanisms, while the roles of most others are still unclear.

Previous studies have implicated the elevated PCAT-1 expression observed in breast cancer.32 However, none of the studies has investigated the biological functions of PCAT-1 in the hypoxic environment that contributed to the malignant progression. Our present study identifies PCAT-1 as a hypoxia-inducible lncRNA and shows a distinct mechanism in breast cancer. Indeed, we find that PCAT-1 overexpression enhances HIF-1α protein stability and confers hypoxia-associated tumorigenesis including growth, migration, invasion, colony formation, and metabolic regulation. When we investigate the mechanisms of PCAT-1 promoting breast cancer under hypoxic conditions, we find that RACK1 is involved and plays a key role. As a multifunctional scaffold protein for many kinases and receptors, RACK1 binds to the PAS-A subdomain of HIF-1α and recruits an Elongin-C E3 ubiquitin ligase complex to HIF-1α, enhancing HIF-1α ubiquitination and degradation. Here, we show that PCAT-1 is capable of controlling the competition of RACK1 for binding to HIF-1α. PCAT-1 is in an important position to control the binding of RACK1 and HSP90 to HIF-1α. By binding to the sixth WD40 domain of RACK1, PCAT-1 prevents RACK1 phosphorylation and dimerization, which are required for RACK1 binding to HIF-1α. Disrupting the binding of RACK1 to HIF-1α by PCAT-1 makes it easier for HIF-1α to bind to HSP90 rather than being degraded by ubiquitin-mediated proteasomal degradation. Thus, PCAT-1 is an essential component of the survival mechanism of the cellular response to hypoxia.

As the expression of PCAT-1, RACK1, HSP90, and HIF-1α is increased in many kinds of cancers,36,38–40 the effects of PCAT-1 on the balance between HIF-1α/RACK1 and HIF-1α/HSP90 may contribute to cancer progression. It is the basis for the association of PCAT-1 with the clinicopathological prognosis of the diseases. As we have shown, PCAT-1 is almost absent or at a low level in the normal tissues, and it increased to a high level in the tumor tissues. Considering the role of PCAT-1 in the upregulation of HIF-1α,
Figure 3. Effects of PCAT-1 on HIF-1α stability

(A) Effects of PCAT-1 overexpression on HIF-1α protein and mRNA expression in MCF-7 cells. (B) Effects of PCAT-1 overexpression on HIF-1α mRNA stability. MCF-7 cells were cultured in normoxia or hypoxia, then the cells were incubated with actinomycin D (5 μg/mL) for 3 h, and the mRNA of HIF-1α was examined at the indicated times by...
facilitation of HIF-1α stability by PCAT-1 may explain the close relation of PCAT-1 overexpression to advanced tumor stage and tumor size. In addition to hypoxia, PCAT-1 also promotes the expression of HIF-1α in normoxia. Since HIF-1α also increases in some cancer cells under normoxic conditions, it can be speculated that PCAT-1 also participates in the regulation of the HIF-1α signaling pathway in normoxia during cancer progression.

It is demonstrated that HIF-1α and its target genes control biological processes in cancers. HIF-1α and the downstream effectors have been considered as potential targets for cancer diagnosis and therapy because of their profound impacts in cancers. However, it is hard to design effective inhibitors because of the complexity of the HIF-1α signaling. Because lncRNA is easy to extract and detect, it has many advantages in cancer diagnosis and prognosis. Our work presents evidence showing that PCAT-1 is an independent risk factor for OS and DFS, suggesting the potential clinical application of PCAT-1 as a biomarker for breast cancer prognosis. Thus, it illustrates that PCAT-1 intervention through gene silencing or other strategies could present a potential new approach to anticancer therapies.

though our study supports that the expression of PCAT-1 is critical to breast cancer in normoxia and hypoxia, PCAT-1 overexpression may be the result of other modulations in cells, and it may be regulated by other factors involved in cancer progression. Our research cannot completely rule out the possibility that PCAT-1 may also enhance HIF-1α stability by regulating other factors that affect HIF-1α degradation. For example, some post-translational modifications, such as acetylation, phosphorylation, nitrosylation, and SUMOylation, have also been reported to be involved in the regulation of HIF-1α expression and activation. These questions should be resolved through future experiments to clarify the role and mechanism of PCAT-1 in breast cancer.

In summary, our studies highlight a previously unknown function of PCAT-1 in cancer progression under hypoxic conditions, especially its role in regulating the oxygen-independent stability of HIF-1α. The effects of PCAT-1 in HIF-1α stability not only provide new insight into the survival mechanism of cells in response to oxygen deficiency but also reveal a potential utility of PCAT-1 in prognosis and therapeutic strategy for breast cancer.

MATERIALS AND METHODS

Cell culture and transfection

Human breast cancer cell lines MCF-7, MDA-MB-231, MDA-MB-468, and T47D, normal breast epithelial cell MCF10A, and human embryonic kidney (HEK) 293 cells were purchased from the American Type Culture Collection (Manassas, VA, USA). The cell lines were cultured in DMEM (Gibco, USA) with 10% fetal bovine serum (FBS), 100 ng/mL streptomycin, and 100 U/mL penicillin. For normoxic conditions, mixed gas consisting of 20% O2, 5% CO2, and 75% N2 at 37°C was used. For hypoxic conditions, the cells were cultured in a gas mixture of 1% O2, 5% CO2, and 94% N2 at 37°C.
Transfection of the cells with siRNAs was performed with Lipofectamine RNAiMAX (Invitrogen, USA) according to the manufacturer’s instructions. For siRNA-mediated knockdown of PCAT-1, two different siRNA sequences were synthesized by GenePharma (Shanghai, China) using the following sequences: si-PCAT-1#1: 5'-AUACACUAAGGAAUU-3'; si-PCAT-1#2: 5'-GACCUAACUCGACUUAAAU-3'. The specific siRNAs for RACK1, HIF-1α, and HIF-2α were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The lentiviral PCAT-1 shRNA (shRNA-PCAT-1) was constructed by Hanbio (Shanghai, China) using the following sequence: 5'-AUACAUAGGCAUGGAAUU-3'.

The PCAT-1, truncated PCAT-1 (Δ1–400), truncated PCAT-1 (Δ401–800), truncated PCAT-1 (Δ801–1200), truncated PCAT-1 (Δ1201–1600), truncated PCAT-1 (Δ1601–1992), truncated PCAT-1 (Δ1201–1992) overexpressed lentiviruses were constructed by Hanbio (Shanghai, China). To express and purify glutathione S-transferase (GST)-RACK1, a full length of RACK1 and its truncated RACK1 cDNAs were amplified by PCR using the appropriate primers and subcloned in frame into pGEX4T-1 to make the GST fusion protein using bacterial expression vectors. The HIF-1α mutant coding plasmid HA-HIF-1α-P402A/P564A-pcDNA3 was purchased from Addgene (Cambridge, MA, USA).

**RNA extraction and quantitative real-time PCR**

Total RNA was extracted by TRIzol Reagent (Invitrogen, USA). Equal amounts of RNA were reverse-transcribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche), and quantitative real-time PCR was performed with the SYBR PrimeScript RT-PCR Kit (Takara, Dalian, China). Unless otherwise specified, the amplified transcript level of each specific gene was normalized against the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA level. The primers were provided by Shengong (Shanghai, China). The primer sequences are listed in Table S3.

**Bioinformatics analysis**

TCGA Breast Cancer datasets were retrieved from the cBioPortal for Cancer Genomics. PCAT-1 gene log2 copy number from TCGA Breast Cancer datasets were retrieved from the cBioPortal and combined with 320 molecular therapy: nucleic acids, volume 24, june 2021.
low or PCAT-1-amplification based on PCAT-1 log2 copy number. The cutoff point of PCAT-1 gene log2 copy number calls on the cases was determined as the value yielding maximum sum of sensitivity and specificity. The clinical data (including the overall survival data and disease-free survival data) were obtained from the TCGA Pan-Cancer Clinical Data Resource. The patients with overall event time <130 months were used in this study. The survival curves were constructed according to the Kaplan-Meier method and compared with the log-rank test.

**Cell growth assay**
The cell growth was monitored by MTT assay. Briefly, cells were treated and cultured into 96-well plates. A total of 20 μL of MTT (Sigma, USA) dissolved in PBS at 5 mg/mL was added to the wells and then incubated for an additional 4 h at 37°C. A total of 100 μL of DMSO was added to dissolve the formed formazan crystals, and the optical density was measured on the microplate reader.

**Colony formation assay**
Cells were seeded in 6-well plates (200 cells/well) and treated for 14 days, and then the cells were fixed with methanol and stained with 1% crystal violet solution. The numbers of cell colonies from three dishes were counted.

**Wound healing and invasion assay**
For the wound healing assays, cells were treated and cultured in 6-well plates until almost totally confluent. Then, the artificial wounds were scratched with a sterile pipette tip, and images were captured at 0 h and 48 h under the microscope.

Cell invasion assays were performed with Transwell chambers (8 μm pores, Corning, USA) coated with Matrigel (BD Biosciences, USA). Cells were treated and suspended in medium with 1% FBS in the upper chambers. Medium containing 10% FBS was used as a chemoattractant in the bottom chamber. After incubation for 24 h, the

---

**Figure 7. PCAT-1 is required in cancer progression and metastasis**

(A) Representative images of tumors in xenograft mouse models bearing MDA-MB-231 cells transfected with shRNA-Control or shRNA-PCAT-1. Tumors were harvested at 5 weeks after implantation. (B) The volume of tumor was measured every 5 days. (C) The weights of tumors were measured after 5 weeks when mice were sacrificed. (D and E) Lung metastasis (D) and liver metastasis (E) in mice were determined by quantitative real-time PCR assays. Data are shown as mean ± SD. **p < 0.01 compared with control. (F–H) Representative H&E images and ISH detection for PCAT-1 in the xenografts (F), lungs (G), and livers (H). Scale bars, 50 μm.
migrated or invaded cells were fixed, stained, and counted under an inverted microscope.

Measurement of ECAR
The ECAR was measured with the Seahorse Extracellular Flux Analyzer XF96 (Seahorse Bioscience, USA) according to the manufacturer’s instructions. Briefly, the treated cells were seeded at a density of \(10^5\) per well and allowed to adhere overnight. Before the assay, the cells were washed with assay medium followed by a sequential injection of 10 mmol/L glucose, 1 μmol/L oligomycin, and 100 mmol/L 2-deoxyglucose (2-DG). ECAR is expressed as mpH/min, and three replicates were performed for each group.

Lactate production assay
Cells were seeded into 6-well plates, and the culture medium was collected for measurement of lactate concentration. The level of lactate in the culture medium was determined with the L-lactate Assay Kit (Abcam, USA), following the manufacturer’s instructions.

Immunoblot analysis and co-immunoprecipitation (coIP)
For immunoblot analysis, radioimmunoprecipitation assay (RIPA) buffer was added and incubated for 30 min, followed by centrifugation; the supernatant contained the total protein. After determination of the protein concentrations by the Bradford method, proteins were separated by SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 5% fat-free milk powder in Tris-buffered saline containing Tween-20 (TBST) buffer and then exposed to primary antibodies at 4°C overnight. After incubation with secondary antibodies, signals were detected with the enhanced chemiluminescence (ECL) detection system.

For immunoprecipitation, protein extracts from the cells were determined by the Bradford method. For the experiment, 500 μg of protein was immunoprecipitated with indicated antibodies at 4°C overnight, followed by incubation with protein A Sepharose beads for 2 h. The immunoprecipitates were washed and resolved by SDS-PAGE and immunoblotted with the indicated antibodies.

RNA pull-down assay
Biotin-labeled PCAT-1 and its fragments were transcribed with Biotin RNA Labeling Mix (Roche) and T7 RNA polymerase (Invitrogen, USA), treated with RNase-free DNase I (Invitrogen, USA), and purified with the RNeasy Mini Kit (QIAGEN, Germany). Pull-downs were performed with biotinylated RNA and cell extracts. The bead-RNA-protein complexes were isolated with streptavidin magnetic beads (Sigma, USA) and subjected to standard immunoblot analysis.

RIP
The RIP assay was performed with the Magna RIP RNA Binding Protein Immunoprecipitation Kit (Millipore, USA). Briefly, cells were harvested and lysed in lysis buffer containing protease inhibitor cocktail and RNase inhibitors. Cell extracts were co-immunoprecipitated using the primary antibody, and the retrieved RNA was subjected to quantitative real-time PCR analysis to demonstrate the presence of the binding products using respective primers.

Xenograft experiments
The animal studies were performed as described previously.47,48 Female BALB/c nude mice (4–5 weeks old) were purchased from Charles River (Beijing, China). All experimental procedures were approved by the Institutional Animal Care and Use Committee of the Second Hospital of Hebei Medical University (Hebei, China). A total of \(10^6\) MDA-MB-231 (transfected with sh-Control or sh-PCAT-1) were injected into the right flank or the tail vein of mice (\(n = 8\)/group), respectively. The tumor volume was measured every 5 days, and tumor volume was estimated by the formula \(V = \frac{1}{2} \times \text{length} \times \text{width}^2\). At the end of the experiment, the tumor tissues in the tumor growth xenograft model were removed and weighed. The lung and liver in the metastasis model were perfused with PBS and subjected to quantitative real-time PCR with primers for human HK2 gene and mouse and human 18S rRNA. The remaining tumor tissues, lung, and liver were fixed in formalin, embedded in paraffin, and analyzed by H&E staining.

ISH
ISH was used to detect the presence of PCAT-1 with digoxigenin-labeled probes designed and synthesized by Exiqon (Shanghai, China). ISH was performed with the ISH Kit (Boster Bio-Engineering, Wuhan, China), and the stains were then scored using the following criteria as described previously:49 0 = negative; 1 = weak staining; 2 = moderate staining; and 3 = strong staining.

Statistical analysis
The overall and disease-free survival curves were calculated by the Kaplan-Meier method, and the differences were assessed with the log-rank test. The nonparametric Mann-Whitney U test served to assess the differences of PCAT-1 expression in clinical specimens. Differences between two independent groups were tested with two-tailed Student’s t test. Comparison of multiple groups was made with one- or two-way ANOVA tests. Univariate and multivariate Cox proportional hazards regression models were performed to explore independent prognostic factors. Data are expressed as mean ± SD. Difference was considered statistically significant at p <0.05.

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.omtn.2021.02.034.
ACKNOWLEDGMENTS
This work was supported by National Natural Science Foundation of China (no. 81402510, 11672332, 11932013), National Key R&D Program of China (no. 2016YFC1101500) and Natural Science Foundation of Tianjin (no. 18JCQNJC09600).

AUTHOR CONTRIBUTIONS
B.L. and J.G. designed the study. J.W., X.C., H.H., Y.S., and N.Z. performed the experiments. J.W., X.X., and X.C. collected clinical samples. M.Y., N.Z., and J.G. analyzed the data. J.G. and B.L. wrote the paper. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Harbeck, N., Penault-Llorca, F., Cortes, J., Ginat, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., and Cardoso, F. (2019). Breast cancer. Nat. Rev. Dis. Primers 5, 66.
2. Waks, A.G., and Winer, E.P. (2019). Breast Cancer Treatment: A Review. JAMA 321, 288–300.
3. Redig, A.J., and McAllister, S.S. (2013). Breast cancer as a systemic disease: a view of metastasis. J. Intern. Med. 274, 113–126.
4. Esteva, F.J., Hubbard-Lucey, V.M., Tang, J., and Pusztai, L. (2019). Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 20, e172–e186.
5. Wouters, B.G., and Koritzinsky, M. (2008). Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat. Rev. Cancer 8, 851–864.
6. Nobre, A.R., Entenberg, D., Wang, Y., Condeelis, J., and Aguirre-Ghiso, J.A. (2018). The Different Routes to Metastasis via Hypoxia-Regulated Programs. Trends Cell Biol. 28, 941–956.
7. Liu, J.N., Bu, W., and Shi, J. (2017). Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia. Chem. Rev. 117, 6160–6224.
8. Palazon, A., Goldrath, A.W., Nizet, V., and Johnson, R.S. (2014). HIF transcription factors, inflammation, and immunity. Immunity 41, 518–528.
9. Choudhry, H., and Harris, A.L. (2018). Advances in Hypoxia-Inducible Factor Biology. Cell Metab. 27, 281–298.
10. Rankin, E.B., and Giaccia, A.J. (2016). Hypoxia control of metastasis. Science 352, 175–180.
11. Semenza, G.L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721–732.
12. Liu, Y.V., and Semenza, G.L. (2007). RACK1 vs. HSP90: competition for HIF-1alpha degradation vs. stabilization. Cell Cycle 6, 656–659.
13. Zhou, Z., Liu, F., Zhang, Z.S., Shu, F., Zheng, Y., Fu, L., and Li, L.Y. (2014). Human rhomboid family-1 suppresses oxygen-independent degradation of hypoxia-inducible factor-1alpha in breast cancer. Cancer Res. 74, 2719–2730.
14. Yang, S.J., Park, Y.S., Cho, J.H., Moon, B., An, H.J., Lee, J.Y., Xie, Z., Wang, Y., Pocylko, D., Lee, D.G., et al. (2017). Regulation of hypoxia responses by flavin adenine dinucleotide-dependent modulation of HIF-1alpha protein stability. EMBO J. 36, 1011–1028.
15. Liu, Y.V., Baek, J.H., Zhang, H., Diez, R., Cole, R.N., and Semenza, G.L. (2007). RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O2-dependent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol. Cell. 25, 207–217.
16. Liu, J., and Esteller, M. (2016). IncRNAs and microRNAs with a role in cancer development. Biochim. Biophys. Acta 1859, 169–176.
17. Ranshoff, J.D., Wei, Y., and Khavar, P.A. (2018). The functions and unique features of long intergenic non-coding RNA. Nat. Rev. Mol. Cell Biol. 19, 143–157.
18. Engertitz, J.M., Ollikainen, N., and Guttmann, M. (2016). Long non-coding RNAs: spatial amplifiers that control nuclear structure and gene expression. Nat. Rev. Mol. Cell Biol. 17, 756–770.
19. Huarte, M. (2015). The emerging role of lncRNAs in cancer. Nat. Med. 21, 1253–1261.
20. Prehn, R.J., and Chinnaiyan, A.M. (2011). The emergence of lncRNAs in cancer biology. Cancer Discov. 1, 391–407.
21. Chang, Y.N., Zhang, K., Hu, Z.M., Qi, H.X., Shi, Z.M., Han, X.H., Han, Y.W., and Hong, W. (2016). Hypoxia-regulated lncRNAs in cancer. Gene 575, 1–8.
22. Prehn, R.J., Iyer, M.K., Balbin, O.A., Dhanasekaran, S.M., Cao, Q., Brenner, J.C., Laxman, B., Asangani, I.A., Grasso, C.S., Kominsky, H.D., et al. (2011). Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 29, 742–749.
23. Ge, X., Chen, Y., Liao, X., Liu, D., Li, F., Ruan, H., and Jia, W. (2013). Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med. Oncol. 30, 588.
37. Shih, J.W., Chiang, W.F., Wu, A.T.H., Wu, M.H., Wang, L.Y., Yu, Y.L., Hung, Y.W., Wang, W.C., Chu, C.Y., Hung, C.L., et al. (2017). Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1α co-activator driving oral cancer progression. Nat. Commun. 8, 15874.

38. Duff, D., and Long, A. (2017). Roles for RACK1 in cancer cell migration and invasion. Cell. Signal. 35, 250–255.

39. Wu, J., Liu, T., Rios, Z., Mei, Q., Lin, X., and Cao, S. (2017). Heat Shock Proteins and Cancer. Trends Pharmacol. Sci. 38, 226–256.

40. Schito, L., and Semenza, G.L. (2016). Hypoxia-Inducible Factors: Master Regulators of Cancer Progression. Trends Cancer 2, 758–770.

41. Lee, Y.H., Bae, H.C., Noh, K.H., Song, K.H., Ye, S.K., Mao, C.P., Lee, K.M., Wu, T.C., and Kim, T.W. (2015). Gain of HIF-1α under normoxia in cancer mediates immune adaptation through the AKT/ERK and VEGFA axes. Clin. Cancer Res. 21, 1438–1446.

42. Keith, B., Johnson, R.S., and Simon, M.C. (2011). HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12, 9–22.

43. Nordgren, I.K., and Tavassoli, A. (2011). Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor. Chem. Soc. Rev. 40, 4307–4317.

44. Yee Koh, M., Spivak-Kroizman, T.R., and Powis, G. (2008). HIF-1 regulation: not so easy come, easy go. Trends Biochem. Sci. 33, 526–534.

45. Kuschel, A., Simon, P., and Tug, S. (2012). Functional regulation of HIF-1α under normoxia—is there more than post-translational regulation? J. Cell. Physiol. 227, 514–524.

46. Liu, J., Lichtenberg, T., Hoadley, K.A., Poisson, L.M., Lazar, A.J., Cherniack, A.D., Kovatich, A.J., Benz, C.C., Levine, D.A., Lee, A.V., et al.; Cancer Genome Atlas Research Network (2018). An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 173, 400–416.e11.

47. Liu, B., Wen, J.K., Li, B.H., Fang, X.M., Wang, J.F., Zhang, Y.P., Shi, C.J., Zhang, D.Q., and Han, M. (2011). Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death Dis. 2, e185.

48. Liu, B., Han, M., Sun, R.H., Wang, J.J., Zhang, Y.P., Zhang, D.Q., and Wen, J.K. (2010). ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation. Breast Cancer Res. 12, R9.

49. Zhang, A., Zhao, J.C., Kim, J., Fong, K.W., Yang, Y.A., Chakravarti, D., Mo, Y.Y., and Yu, J. (2015). LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer. Cell Rep. 13, 209–221.